| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 08/20/2002 | US6436680 Isolated bacterial strain of genus vibrio that belongs to species called vibrio diabolicus and possesses specified characteristics; produces exopolysaccharides useful in preparing medicines |
| 08/20/2002 | US6436447 Evacuant |
| 08/20/2002 | US6436441 Hydrogel-forming sustained-release preparation |
| 08/20/2002 | US6436440 Use of N-vinyllactam-or-N-vinylamine-containing copolymers as matrix for producing solid pharmaceutical and cosmetic presentations |
| 08/20/2002 | US6436437 Covalent polar lipid conjugates with neurologically active compounds for targeting |
| 08/20/2002 | US6436433 Transdermal or topical plaster system with a polyacrylate matrix with improved physical properties |
| 08/20/2002 | US6436430 Self-emulsifying compositions for drugs poorly soluble in water |
| 08/20/2002 | US6436428 Device and method for treating urinary incontinence in females |
| 08/20/2002 | US6436425 Administering aqueous formulation comprising polyoxyalkylene block cpolymer and water to tissues of mammal for inhibiting the formation/reformation of internal adhesions |
| 08/20/2002 | US6436414 Active ingredient combinations or adducts of biotin and/or biotin derivatives and cyclodextrins and use of such active ingredient combinations in cosmetic preparations |
| 08/20/2002 | US6436403 Pharmaceutical composition of the intercellular adhesion molecule ICAM-1 for use in anti-viral prophylactic therapy |
| 08/20/2002 | US6436402 Process for making human papillomavirus virus-like particles with improved properties |
| 08/20/2002 | US6436397 Reducing autodegradation during processing and purification. lyophilized solutioni with bulking agent, sucrose, trehalose, or raffinose |
| 08/20/2002 | US6436394 Adenovirus vectors specific for cells expressing androgen receptor and methods of use thereof |
| 08/20/2002 | US6436386 Hydroxyapatite-targeting poly (ethylene glycol) and related polymers |
| 08/20/2002 | US6436369 Anti-plaque emulsions and products containing same |
| 08/20/2002 | US6436368 Process for preparing beclomethasone dipropionate freon® clathrate |
| 08/20/2002 | US6436344 Method of inactivating pathogens |
| 08/20/2002 | US6435873 Medication delivery devices |
| 08/20/2002 | CA2271895C Substituted amylose as a matrix for sustained drug release |
| 08/20/2002 | CA2255663C Antifungal composition with enhanced bioavailability |
| 08/20/2002 | CA2197496C Composition including a dispersion of polymeric particles in a non-aqueous medium |
| 08/20/2002 | CA2182577C Lipophilic carrier preparations |
| 08/20/2002 | CA2150372C Stable oral ci-981 formulation and process of preparing same |
| 08/20/2002 | CA2111697C A process for producing suppositories by compression and suppositories obtained by the process |
| 08/20/2002 | CA2106573C Debridement of bodily cavities using debridement fluids |
| 08/20/2002 | CA2063886C Polyethylene protein conjugates |
| 08/15/2002 | WO2002063010A2 Method of producing recombinant antibodies against tumors |
| 08/15/2002 | WO2002062972A2 Hybridoma cell line g250 and its use for producing monoclonal antibodies |
| 08/15/2002 | WO2002062947A2 Hematopoietic growth factor inducible neurokinin-1 gene |
| 08/15/2002 | WO2002062843A2 Modified erythropoietin (epo) with reduced immunogenicity |
| 08/15/2002 | WO2002062842A1 Modified keratinocyte growth factor (kgf) with reduced immunogenicity |
| 08/15/2002 | WO2002062833A2 Modified leptin with reduced immunogenicity |
| 08/15/2002 | WO2002062832A2 Modified human brain-derived neutrophic factor (bdnf) with reduced immunogenicity |
| 08/15/2002 | WO2002062810A2 Linkable sialyl lewis x analogs |
| 08/15/2002 | WO2002062806A1 Organofunctionalized per-b-hydroxy polyhedral boranes |
| 08/15/2002 | WO2002062766A2 Melanocortin-4 receptor binding compounds and methods of use thereof |
| 08/15/2002 | WO2002062422A1 Novel compositions of potassium channel openers and protein kinase c inhibitors and use thereof |
| 08/15/2002 | WO2002062397A2 Chelates of metals which can be activated by neutrons and their use for the measurement of labeled specimens |
| 08/15/2002 | WO2002062396A2 Enhanced oral and transcompartmental delivery of therapeutic or diagnostic agents using polymer conjugates |
| 08/15/2002 | WO2002062395A2 A method and system for introducing a gene into a human stem cell |
| 08/15/2002 | WO2002062393A2 Coating for orally administered compositions |
| 08/15/2002 | WO2002062392A2 Water-soluble compositions of bioactive lipophilic compounds |
| 08/15/2002 | WO2002062375A1 Modified interleukin-1 receptor antagonist (il-1ra) with reduced immunogenicity |
| 08/15/2002 | WO2002062357A1 Methods and devices for tissue repair |
| 08/15/2002 | WO2002062356A2 Monovalent-selective cation exchangers as oral sorbent therapy |
| 08/15/2002 | WO2002062350A1 Methods for the administration of amifostine and related compounds |
| 08/15/2002 | WO2002062338A1 Parenteral formulation containing epothilone analogs |
| 08/15/2002 | WO2002062336A1 Antifungal remedy formulation for external application |
| 08/15/2002 | WO2002062331A1 Cyanoacrylate compositions for prophylactic or therapeutic treatment of diseases manifesting themselves in and/or damaging cutaneous tissue |
| 08/15/2002 | WO2002062330A2 Use of (r)-ibuprofen methanesulfonamide and salts thereof in the treatment and prevention of rejection reactions of transplanted organs |
| 08/15/2002 | WO2002062326A1 Parasiticidal compositions and methods of use |
| 08/15/2002 | WO2002062320A1 Methods and compositions for reducing the taste of pharmaceutically active agents |
| 08/15/2002 | WO2002062318A2 Oral itraconazole formulations and methods of making the same |
| 08/15/2002 | WO2002062310A1 Multifunctional particulate additive for personal care and cosmetic compositions, and the process of making the same |
| 08/15/2002 | WO2002062304A2 Cosmetic and/or pharmaceutical agents containing an acylated amino acid and a protein condensate |
| 08/15/2002 | WO2002062276A1 Dehydrated hydrogel precursor-based, tissue adherent compositions and methods of use |
| 08/15/2002 | WO2002062260A2 Improved ophthalmic and contact lens solutions containing forms of vitamin b |
| 08/15/2002 | WO2002051800A3 Sulphur-containing amphiphilic agents for the transfer of biologically active molecules into cells |
| 08/15/2002 | WO2002047685A3 Nmda receptor agonist pharmaceutical compositions |
| 08/15/2002 | WO2002032459A3 Method of increasing the efficacy of antibiotics by complexing with cyclodextrins |
| 08/15/2002 | WO2002022160A3 The diagnosis, prevention, amelioration and/or treatment of disturbed immune function induced by disturbed lipid metabolism |
| 08/15/2002 | WO2002015938A3 Testosterone ester formulation for human use |
| 08/15/2002 | WO2002007707A3 Linkage of agents using microparticles |
| 08/15/2002 | WO2002003848A3 Method for opening the blood-brain barrier |
| 08/15/2002 | WO2002000263A3 Tripeptide prodrug compounds |
| 08/15/2002 | WO2002000195A3 Methods and compositions for treating pain of the mucous membrane |
| 08/15/2002 | WO2001095945A3 Prodrug compounds cleavable by thimet oligopeptidase |
| 08/15/2002 | WO2001078786A3 High affinity peptide-containing nanoparticles |
| 08/15/2002 | WO2001034801A9 Recombinant gelatin in vaccines |
| 08/15/2002 | WO2001032222A9 Selective toxin expression in angiogenic endothelial cells |
| 08/15/2002 | US20020111366 Therapy for brain disorders; strokes |
| 08/15/2002 | US20020111360 Quinazoline formulations and therapeutic use thereof |
| 08/15/2002 | US20020111338 Bile-acid conjugates for providing sustained systemic concentrations of drugs |
| 08/15/2002 | US20020111336 Topical composition |
| 08/15/2002 | US20020111303 Protein found in breast, prostate gland cells cancer membrane |
| 08/15/2002 | US20020111300 Methods for reduced renal uptake of protein conjugates |
| 08/15/2002 | US20020111294 Administering an organocobalt complex |
| 08/15/2002 | US20020111281 Cosmetics, drugs |
| 08/15/2002 | US20020110895 Nucleotide sequences coding enzymatic polypeptide for use in treatment of thrombosis and in the immune defects |
| 08/15/2002 | US20020110869 Polynucleotide encoding chimeric protein and related vector, cell and method of expression thereof |
| 08/15/2002 | US20020110633 Process for producing a powder containing crystalline particles of maltitol |
| 08/15/2002 | US20020110608 Compositions which inhibit apoptosis, methods of purifying the compositions and uses thereof |
| 08/15/2002 | US20020110597 Redispersibility upon administration to human or animal |
| 08/15/2002 | US20020110586 Liposomal antineoplastic drugs and uses thereof |
| 08/15/2002 | US20020110585 Enhanced ability to camouflage wrinkles and swelling, greater permeability of the backing to water vapor and oxygen, flexibility and conformability, and thus, enhanced comfort |
| 08/15/2002 | US20020110577 Method and non-gelling composition for inhibiting post-surgical adhesions |
| 08/15/2002 | US20020110561 For use in therapy, sustained release of drugs |
| 08/15/2002 | US20020110559 Confering an immune response to a tumor cell in a mammal by administering antibody which binds to aspartyl (asparaginyl) beta hydroxylase (HAAH) |
| 08/15/2002 | US20020110557 Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use |
| 08/15/2002 | US20020110552 Stabilized liquid preparation of the protease which activates blood coagulation factor VII, or of its proenzyme |
| 08/15/2002 | US20020110539 Modulated release particles for lung delivery |
| 08/15/2002 | US20020110535 Multivalent platform molecules comprising high molecular weight polyethylene oxide |
| 08/15/2002 | US20020110529 Inhalable powder containing tiotropium |
| 08/15/2002 | US20020110528 Stability, aerosols, drug delivery; therapy |
| 08/15/2002 | US20020110527 Stability, aerosols, drug delivery; therapy |
| 08/15/2002 | US20020110526 Modulated release particles for lung delivery |
| 08/15/2002 | US20020110525 Modulated release particles for lung delivery |
| 08/15/2002 | US20020110524 Method for stabilizing biomolecules in liquid formulations |
| 08/15/2002 | US20020108533 A hardenable propylene glycol alginate (PGA) film-former and a surfactant in an aqueous solution of low viscosity; prompt release for drug and veterinary solid dosage forms, candy, seeds, animal feed, fertilizers, pesticides and foods |